Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine

Immunobiology

Volumn 219, Issue 2, 2014, Pages 97-103

  Yin, Ying ^a   Zhang, Sheng ^a,b   Cai, Chenguang ^a   Zhang, Jun ^a   Dong, Dayong ^a   Guo, Qiang ^a   Fu, Ling ^a   Xu, Junjie ^a   Chen, Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b People' Republic of China   (China)

Author keywords

Anthrax; Deletion modification; Epitope vaccine; HBc; Major immunodominant region

Indexed keywords

ANTHRAX VACCINE; HEPATITIS B CORE H144DL2 VACCINE; HEPATITIS B CORE H144L2 VACCINE; HEPATITIS B CORE N144 PROTECTIVE ANTIGEN LOOP2 VACCINE; MOLECULAR SCAFFOLD; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CHEMICAL MODIFICATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DELETION MODIFICATION; DRUG EFFICACY; DRUG PURIFICATION; DRUG STRUCTURE; FEMALE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; MAJOR IMMUNODOMINANT REGION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION;

AA; AMINO ACID(S); ANTHRAX; DELETION MODIFICATION; EPITOPE VACCINE; HBC; HBC-N144; HBC-N144-PA-LOOP2; HBCAG; HBCL2; HBV; HEPATITIS B VIRUS; HEPATITIS B VIRUS CORE ANTIGEN; HEPATITIS B VIRUS CORE PROTEIN; LETHAL TOXIN; LETX; MAJOR IMMUNODOMINANT REGION; MIR; N-TERMINAL 144 AMINO ACIDS OF HBC; PA; PROTECTIVE ANTIGEN; RECOMBINANT LETHAL FACTOR; RECOMBINANT PROTECTIVE ANTIGEN; RLF; RPA; VIRUS LIKE PARTICLE; VLP;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; EPITOPES, B-LYMPHOCYTE; FEMALE; GENETIC VECTORS; HEPATITIS B VIRUS; HUMANS; IMMUNODOMINANT EPITOPES; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; VIRAL CORE PROTEINS; VIRION;

EID: 84891827129     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2013.08.008     Document Type: Article

References (38)

1. Aguilar J.C., Lobaina Y., Muzio V., García D., Pentón E., Iglesias E., Pichardo D., Urquiza D., Rodríguez D., Silva D., Petrovsky N., Guillén G. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol. Cell Biol. 2004, 82:539-546.
2. Arnold K., Bordoli L., Kopp J., Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
3. Billaud J.N., Peterson D., Schodel F., Chen A., Sallberg M., Garduno F., Goldstein P., McDowell W., Hughes J., Jones J., Milich D. Comparative antigenicity and immunogenicity of hepadnavirus core proteins. J. Virol. 2005, 79:13641-13655.
4. Billaud J.N., Peterson D., Barr M., Chen A., Sallberg M., Garduno F., Goldstein P., McDowell W., Hughes J., Jones J., Milich D. Combinatorial approach to hepadnavirus-like particle vaccine design. J. Virol. 2005, 79:13656-13666.
5. Billaud J.N., Peterson D., Lee B.O., Maruyama T., Chen A., Sallberg M., Garduno F., Goldstein P., Hughes J., Jones J., Milich D. Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine 2007, 25:1593-1606.
6. Blokhina E.A., Kuprianov V.V., Stepanova L.A., Tsybalova L.M., Kiselev O.I., Ravin N.V., Skryabin K.G. A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles. Virology 2013, 435:293-300.
7. Braun S., Bruvere R., Bruvere A., Alekseeva E., Kozlovska T. Subcellular localization of hepatitis B virus core protein expressed from two different constructs in the Semliki Forest virus expression system. Acta Univ. Latviensis 2008, 745:7-15.
8. Collier R.J., Young J.A. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 2003, 19:45-70.
9. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londono-Arcila P., Fiers W., Saelens X. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008, 26:6503-6507.
10. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A "universal" human influenza A vaccine. Virus Res. 2004, 103:173-176.
11. Freivalds J., Dislers A., Ose V., Pumpens P., Tars K., Kazaks A. Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris. Protein Expr. Purif. 2011, 75:218-224.
12. Friedlander A.M., Little S.F. Advances in the development of next-generation anthrax vaccines. Vaccine 2009, 27(Suppl. 4):D28L 32.
13. Gallina A., Bonelli F., Zentilin L., Rindi G., Muttini M., Milanesi G. A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids. J. Virol. 1989, 63:4645-4652.
14. Geldmacher A., Skrastina D., Borisova G., Petrovskis I., Krüger D.H., Pumpens P., Ulrich R. A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies. Vaccine 2005, 23:3973-3983.
15. Goldsby R.A., Kindt T.J., Kuby J., Osborne B.A. Immunology 2006, 57-75. W.H. Freeman, New York. 5th ed.
16. Gregson A.L., Oliveira G., Othoro C., Calvo-Calle J.M., Thorton G.B., Nardin E., Edelman R. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS ONE 2008, 3:e1556.
17. Guex N., Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997, 18:2714-2723.
18. Karpenko L.I., Ivanisenko V.A., Pika I.A., Chikaev N.A., Eroshkin A.M., Veremeiko T.A., Ilyichev A.A. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids 2000, 18:329-337.
19. Kushnir N., Streatfield S.J., Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012, 31:58-83.
20. Liu J., Cai C., Guo Q., Zhang J., Dong D., Li G., Fu L., Xu J., Chen W. Secretory expression and efficient purification of recombinant anthrax toxin lethal factor with full biological activity in E. coli. Protein Expr. Purif. 2013, 89:56-61.
21. Milich D.R., Chen M., Schodel F., Peterson D.L., Jones J.E., Hughes J.L. Role of B cells in antigen presentation of the hepatitis B core. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14648-14653.
22. Mock M., Fouet A. Anthrax. Annu. Rev. Microbiol. 2001, 55:647-671.
23. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Wetzel K., Maier C., Birkett A.J., Sarpotdar P., Corado M.L., Thornton G.B., Schmidt A. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. 2004, 72:6519-6527.
24. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999, 5:1157-1163.
25. Oliveira G.A., Wetzel K., Calvo-Calle J.M., Nussenzweig R., Schmidt A., Birkett A., Dubovsky F., Tierney E., Gleiter C.H., Boehmer G., Luty A.J., Ramharter M., Thornton G.B., Kremsner P.G., Nardin E.H. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect. Immun. 2005, 73:3587-3597.
26. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature 1997, 385:833-838.
27. Pumpens P., Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001, 44:98-114.
28. Ravin N.V., Kotlyarov R.Y., Mardanova E.S., Kuprianov V.V., Migunov A.I., Stepanova L.A., Tsybalova L.M., Kiselev O.I., Skryabin K.G. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry 2012, 77:33-40.
29. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev. Vaccines 2009, 8:499-508.
30. Schwede T., Kopp J., Guex N., Peitsch M.C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 2003, 31:3381-3385.
31. Ulrich R., Nassal M., Meisel H., Kruger D.H. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv. Virus Res. 1998, 50:141-182.
32. Walker A., Skamel C., Nassal M. SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure. Sci. Rep. 2011, 1:5.
33. Whitacre D.C., Lee B.O., Milich D.R. Use of hepadnavirus core proteins as vaccine platforms. Expert Rev. Vaccines 2009, 8:1565-1573.
34. Wynne S.A., Crowther R.A., Leslie A.G. The crystal structure of the human hepatitis B virus capsid. Mol. Cell 1999, 3:771-780.
35. Yin Y., Zhang J., Dong D., Liu S., Guo Q., Song X., Li G., Fu L., Xu J., Chen W. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis. Vaccine 2008, 26:5814-5821.
36. Young J.A., Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 2007, 76:243-265.
37. Zeltins A. Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 2013, 53:92-107.
38. Zhang J., Xu J., Li G., Dong D., Song X., Guo Q., Zhao J., Fu L., Chen W. The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Biochem. Biophys. Res. Commun. 2006, 341:1164-1171.